Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Perioperative Enfortumab Vedotin + Pembrolizumab vs Gemcitabine + Cisplatin in Muscle-Invasive Urothelial Carcinoma
2020-003106-31Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) and muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Event-Free Survival (EFS). Started Dec 2020; status: active.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2020-003106-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003106-31.